Loading...

Buy Full Version
"Cephalosporin Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

LI_173510
Pages: 239
Mar 2019 | 9246 Views
 
Author(s) : Surabhi Pandey & Onkar Sumant
Tables: 166
Charts: 35
 

Cephalosporin Market Outlook - 2025

The global cephalosporin market size was valued at $11,869 million in 2017, and is estimated to reach $14,022 million by 2025, growing at a CAGR of 2.0% from 2018 to 2025.

Cephalosporin is a bactericidal, broad-spectrum, β-lactam antibiotic originally derived from the fungus Acremonium that is used to treat bacterial infections such as pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, gonorrhea, and others. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. Increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea drives the market growth. In addition, increase in R&D activities to develop highly efficient & safe drugs, upsurge in use of combination therapies boost the growth of the market, and rise in incidence of pneumonia, tonsillitis, bronchitis, & gonorrhea. Hence, these aforementioned factors helps in increasing the global cephalosporin market share.

Cephalosporin market

Get more information on this report : Request Sample Pages

The global cephalosporin market is experiencing growth owing to surge in prevalence of infectious diseases, increase in R&D activities for the development of combination drugs, and rise in funding for the development of antibiotics. In addition, rising demand for the antibacterial further drives the growth the global cephalosporin market. However, side effects associated with cephalosporin, uncertain regulatory reforms, antibiotic resistance to cephalosporin, and less drugs in pipeline are projected to impede the cephalosporin market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer remunerative opportunities for the market players.

The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics. Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Cephalosporin market by Generation

Get more information on this report : Request Sample Pages
 
Generation segment review

Based on generation, the third-generation cephalosporin segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as these are used for the treatment of Gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, pyelonephritis, skin & soft tissue infections, Lyme disease, and gonorrhea. However, the fifth-generation cephalosporin is expected to register highest CAGR during the forecast period, as these drugs possess strong activity against aerobic Gram-negative bacteria and exceptional activity against aerobic Gram-positive bacteria.

Cephalosporin market by Type

Get more information on this report : Request Sample Pages

Type segment review

Based on the type, the branded cephalosporin drugs segment is projected to exhibit the highest growth during the forecast period, as these drugs are developed by using expensive R&D activities that are conducted by a manufacturer. After the drug approval, a 20-year patent is issued to the manufacturing company for the sale of the branded drug in the market. Hence, branded drugs assure quality and effectiveness over generic drugs.

Cephalosporin market by Region

Get more information on this report : Request Sample Pages

Region segment review

Based on region, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increased consumption of cephalosporin, its easy availability, and rise in sale of over-the-counter drugs, and increase in bacterial infection in the region. However, LAMEA is projected to register the highest CAGR during the forecast period, owing to increase in incidence of infectious diseases. In addition, rise in healthcare expenditure is anticipated to offer a lucrative opportunity for the market growth.

The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, namely, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, Shionogi, and others.

Key Benefits for Cephalosporin Market:

  • This report provides a detailed quantitative analysis of the current cephalosporin market trends and cephalosporin market forecast estimations from 2018 to 2025, which assists to identify the prevailing cephalosporin market opportunities.
  • An in-depth cephalosporin market analysis includes analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global cephalosporin market is provided.
  • Region-wise and country-wise cephalosporin market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current trends and future market potential from 2018 to 2025 in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the cephalosporin market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global cephalosporin market.

Cephalosporin Key Market Segments:

By Generation

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin  
  • Fifth-generation Cephalosporin

By Type

  • Branded
  • Generics

By Route of Drug Administration

  • Injection
  • Oral

By Application

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report Description
1.2.    Key Benefits for Stakeholders
1.3.    Key Market Segments

1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key Findings

3.2.1.    Top investment pockets

3.3.    Top winning strategies

3.3.1.    Top Winning Strategies, by year, 2015-2018*
3.3.2.    Top Winning Strategies, by development, 2015-2018* (%)
3.3.3.    Top Winning Strategies, by company, 2015-2018*
3.3.4.    Market Dynamics
3.3.5.    Drivers

3.3.5.1.    Surge in incidence of infectious diseases
3.3.5.2.    Increase in R&D activities for the development of combination drugs
3.3.5.3.    Rise in funding for the development of antibiotics

3.3.6.    Restraints

3.3.6.1.    Side effects associated with cephalosporin
3.3.6.2.    Antibiotic resistance to cephalosporin

3.3.7.    Opportunities

3.3.7.1.    Lucrative opportunities in the emerging economies

3.4.    Market Share Analysis, 2017
3.5.    Porter’s Five Forces Analysis
3.6.    Novel Molecules in Cephalosporin Market

3.6.1.    Ceftazidime
3.6.2.    Cefuroxime

3.7.    Combination Therapies in Cephalosporin Market

CHAPTER 4:    CEPHALOSPORIN MARKET, BY GENERATION

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    First-Generation Cephalosporin

4.2.1.    Key market trends
4.2.2.    Growth factors and opportunities
4.2.3.    Market size and forecast

4.3.    Second-Generation Cephalosporin

4.3.1.    Key market trends
4.3.2.    Growth factors and opportunities
4.3.3.    Market size and forecast

4.4.    Third-Generation Cephalosporin

4.4.1.    Key market trends
4.4.2.    Growth factors and opportunities
4.4.3.    Market size and forecast

4.5.    Fourth-Generation Cephalosporin

4.5.1.    Key market trends
4.5.2.    Growth factors and opportunities
4.5.3.    Market size and forecast

4.6.    Fifth-Generation Cephalosporin

4.6.1.    Key market trends
4.6.2.    Growth factors and opportunities
4.6.3.    Market size and forecast

CHAPTER 5:    CEPHALOSPORIN MARKET, BY TYPE

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Branded Cephalosporin drugs

5.2.1.    Market size and forecast

5.3.    Generic Cephalosporin Drugs

5.3.1.    Market size and forecast

CHAPTER 6:    CEPHALOSPORIN MARKET,  BY ROUTE OF DRUG ADMINISTRATION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Cephaloshorin Injections

6.2.1.    Market size and forecast

6.3.    Oral Cephalosporin Drugs

6.3.1.    Market size and forecast

CHAPTER 7:    CEPHALOSPORIN MARKET, BY APPLICATION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    Respiratory Tract Infection

7.2.1.    Market size and forecast

7.3.    Skin Infection

7.3.1.    Market size and forecast

7.4.    Ear Infection

7.4.1.    Market size and forecast

7.5.    Urinary Tract Infection

7.5.1.    Market size and forecast

7.6.    Sexually Transmitted Infection

7.6.1.    Market size and forecast

7.7.    Others

7.7.1.    Market size and forecast

CHAPTER 8:    CEPHALOSPORIN MARKET, BY REGION

8.1.    Overview

8.1.1.    Market size and forecast

8.2.    North America

8.2.1.    Key market trends

8.2.2.    Growth factors and opportunities
8.2.3.    North America cephalosporin market by country

8.2.3.1.    U.S.

8.2.3.1.1.    U.S. cephalosporin market by generation
8.2.3.1.2.    U.S. cephalosporin market by type
8.2.3.1.3.    U.S. cephalosporin market by route of drug administration
8.2.3.1.4.    U.S. cephalosporin market by application

8.2.3.2.    Canada

8.2.3.2.1.    Canada cephalosporin market by generation
8.2.3.2.2.    Canada cephalosporin market by type
8.2.3.2.3.    Canada cephalosporin market by route of drug administration
8.2.3.2.4.    Canada cephalosporin market by application

8.2.3.3.    Mexico

8.2.3.3.1.    Mexico cephalosporin market by generation
8.2.3.3.2.    Mexico cephalosporin market by type
8.2.3.3.3.    Mexico cephalosporin market by route of drug administration
8.2.3.3.4.    Mexico cephalosporin market by application

8.2.4.    North America cephalosporin market by generation
8.2.5.    North America cephalosporin market by type
8.2.6.    North America cephalosporin market by route of drug administration
8.2.7.    North America cephalosporin market by application

8.3.    Europe

8.3.1.    Key market trends
8.3.2.    Growth factors and opportunities
8.3.3.    Europe cephalosporin market by country

8.3.3.1.    Germany

8.3.3.1.1.    Germany cephalosporin market by generation
8.3.3.1.2.    Germany cephalosporin market by type
8.3.3.1.3.    Germany cephalosporin market by route of drug administration
8.3.3.1.4.    Germany cephalosporin market by application

8.3.3.2.    France

8.3.3.2.1.    France cephalosporin market by generation
8.3.3.2.2.    France cephalosporin market by type
8.3.3.2.3.    France cephalosporin market by route of drug administration
8.3.3.2.4.    France cephalosporin market by application

8.3.3.3.    UK

8.3.3.3.1.    UK cephalosporin market by generation
8.3.3.3.2.    UK cephalosporin market by type
8.3.3.3.3.    UK cephalosporin market by route of drug administration
8.3.3.3.4.    UK cephalosporin market by application

8.3.3.4.    Italy

8.3.3.4.1.    Italy cephalosporin market by generation
8.3.3.4.2.    Italy cephalosporin market by type
8.3.3.4.3.    Italy cephalosporin market by route of drug administration
8.3.3.4.4.    Italy cephalosporin market by application

8.3.3.5.    Spain

8.3.3.5.1.    Spain cephalosporin market by generation
8.3.3.5.2.    Spain cephalosporin market by type
8.3.3.5.3.    Spain cephalosporin market by route of drug administration
8.3.3.5.4.    Spain cephalosporin market by application

8.3.3.6.    Rest of Europe

8.3.3.6.1.    Rest of Europe cephalosporin market by generation
8.3.3.6.2.    Rest of Europe cephalosporin market by type
8.3.3.6.3.    Rest of Europe cephalosporin market by route of drug administration
8.3.3.6.4.    Rest of Europe cephalosporin market by application

8.3.4.    Europe cephalosporin market by generation
8.3.5.    Europe cephalosporin market by type
8.3.6.    Europe cephalosporin market by route of drug administration
8.3.7.    Europe cephalosporin market by application

8.4.    ASIA-PACIFIC

8.4.1.    Key market trends
8.4.2.    Growth factors and opportunities
8.4.3.    Asia-Pacific cephalosporin market by country

8.4.3.1.    Japan

8.4.3.1.1.    Japan cephalosporin market by generation
8.4.3.1.2.    Japan cephalosporin market by type
8.4.3.1.3.    Japan cephalosporin market by route of drug administration
8.4.3.1.4.    Japan cephalosporin market by application

8.4.3.2.    China

8.4.3.2.1.    China cephalosporin market by generation
8.4.3.2.2.    China cephalosporin market by type
8.4.3.2.3.    China cephalosporin market by route of drug administration
8.4.3.2.4.    China cephalosporin market by application

8.4.3.3.    India

8.4.3.3.1.    India cephalosporin market by generation
8.4.3.3.2.    India cephalosporin market by type
8.4.3.3.3.    India cephalosporin market by route of drug administration
8.4.3.3.4.    India cephalosporin market by application

8.4.3.4.    Australia

8.4.3.4.1.    Australia cephalosporin market by generation
8.4.3.4.2.    Australia cephalosporin market by type
8.4.3.4.3.    Australia cephalosporin market by route of drug administration
8.4.3.4.4.    Australia cephalosporin market by application

8.4.3.5.    South Korea

8.4.3.5.1.    South Korea cephalosporin market by generation
8.4.3.5.2.    South Korea cephalosporin market by type
8.4.3.5.3.    South Korea cephalosporin market by route of drug administration
8.4.3.5.4.    South Korea cephalosporin market by application

8.4.3.6.    Rest of Asia-Pacific

8.4.3.6.1.    Rest of Asia-Pacific cephalosporin market by generation
8.4.3.6.2.    Rest of Asia-Pacific cephalosporin market by type
8.4.3.6.3.    Rest of Asia-Pacific cephalosporin market by route of drug administration
8.4.3.6.4.    Rest of Asia-Pacific cephalosporin market by application

8.4.4.    Asia-Pacific cephalosporin market by generation
8.4.5.    Asia-Pacific cephalosporin market by type
8.4.6.    Asia-Pacific cephalosporin market by route of drug administration
8.4.7.    Asia-Pacific cephalosporin market by application

8.5.    LAMEA

8.5.1.    Key market trends
8.5.2.    Growth factors and opportunities
8.5.3.    LAMEA cephalosporin market by country

8.5.3.1.    Brazil

8.5.3.1.1.    Brazil cephalosporin market by generation
8.5.3.1.2.    Brazil cephalosporin market by type
8.5.3.1.3.    Brazil cephalosporin market by route of drug administration
8.5.3.1.4.    Brazil cephalosporin market by application

8.5.3.2.    South Africa

8.5.3.2.1.    South Africa cephalosporin market by generation
8.5.3.2.2.    South Africa cephalosporin market by type
8.5.3.2.3.    South Africa cephalosporin market by route of drug administration
8.5.3.2.4.    South Africa cephalosporin market by application

8.5.3.3.    Saudi Arabia

8.5.3.3.1.    Saudi Arabia cephalosporin market by generation
8.5.3.3.2.    Saudi Arabia cephalosporin market by type
8.5.3.3.3.    Saudi Arabia cephalosporin market by route of drug administration
8.5.3.3.4.    Saudi Arabia cephalosporin market by application

8.5.3.4.    Rest of LAMEA

8.5.3.4.1.    Rest of LAMEA cephalosporin market by generation
8.5.3.4.2.    Rest of LAMEA cephalosporin market by type
8.5.3.4.3.    Rest of LAMEA cephalosporin market by route of drug administration
8.5.3.4.4.    Rest of LAMEA cephalosporin market by application

8.5.4.    LAMEA cephalosporin market by generation
8.5.5.    LAMEA cephalosporin market by type
8.5.6.    LAMEA cephalosporin market by route of drug administration
8.5.7.    LAMEA cephalosporin market by application

CHAPTER 9:    COMPANY PROFILES

9.1.    Allergan Plc.

9.1.1.    Company overview
9.1.2.    Company snapshot
9.1.3.    Operating business segments
9.1.4.    Product portfolio
9.1.5.    Business performance
9.1.6.    Key strategic moves and developments

9.2.    Bristol-Myers Squibb Company

9.2.1.    Company overview
9.2.2.    Company snapshot
9.2.3.    Operating business segment
9.2.4.    Product portfolio
9.2.5.    Business performance

9.3.    F. Hoffmann-La Roche Ltd.

9.3.1.    Company overview
9.3.2.    Company snapshot
9.3.3.    Operating business segments
9.3.4.    Product portfolio
9.3.5.    Business performance
9.3.6.    Key strategic moves and developments

9.4.    GlaxoSmithKline plc

9.4.1.    Company overview
9.4.2.    Company snapshot
9.4.3.    Operating business segments
9.4.4.    Product portfolio
9.4.5.    Business performance

9.5.    Lupin Limited (Lupin Pharmaceuticals, Inc.)

9.5.1.    Company overview
9.5.2.    Company snapshot
9.5.3.    Operating business segments
9.5.4.    Product portfolio
9.5.5.    Business performance

9.6.    Merck & Co. Inc.

9.6.1.    Company overview
9.6.2.    Company snapshot
9.6.3.    Operating business segments
9.6.4.    Product portfolio
9.6.5.    Business performance
9.6.6.    Key strategic moves and developments

9.7.    Novartis International AG (Sandoz)

9.7.1.    Company overview
9.7.2.    Company snapshot
9.7.3.    Operating business segments
9.7.4.    Product portfolio
9.7.5.    Business performance

9.8.    Pfizer Inc.

9.8.1.    Company overview
9.8.2.    Company snapshot
9.8.3.    Operating business segments
9.8.4.    Product portfolio
9.8.5.    Business performance
9.8.6.    Key strategic moves and developments

9.9.    Sanofi

9.9.1.    Company overview
9.9.2.    Company snapshot
9.9.3.    Operating business segments
9.9.4.    Product portfolio
9.9.5.    Business performance
9.9.6.    Key strategic moves and developments

9.10.    Teva Pharmaceutical Industries Ltd.

9.10.1.    Company overview
9.10.2.    Company snapshot
9.10.3.    Operating business segments
9.10.4.    Product portfolio
9.10.5.    Business performance

LIST OF TABLES

TABLE 01.    TOTAL COMMITTED PUBLIC FUNDING FOR ANTIBACTERIAL RESISTANCE RESEARCH BY JPIAMR COUNTRIES
TABLE 02.    RECOMMENDED DOSAGE SCHEDULE FOR CEFTAZIMIDE
TABLE 03.    AVERAGE SELLING PRICE ($) OF CEFTAZIMIDE
TABLE 04.    RECOMMENDED DOSAGE SCHEDULE FOR CEFTIN
TABLE 05.    CEFUROXIME MARKET VALUE, 2017–2025 ($MILLION)
TABLE 06.    AVERAGE SELLING PRICE ($) OF CEFUROXIME
TABLE 07.    NONCLASSIFIED AND COMBINATION CEPHALOSPORIN
TABLE 08.    GLOBAL CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 09.    FIRST-GENERATION CEPHALOSPORIN
TABLE 10.    FIRST-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 11.    SECOND-GENERATION CEPHALOSPORIN
TABLE 12.    SECOND-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 13.    THIRD-GENERATION CEPHALOSPORIN
TABLE 14.    THIRD-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 15.    FOURTH-GENERATION CEPHALOSPORIN
TABLE 16.    FOURTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 17.    FIFTH-GENERATION CEPHALOSPORIN
TABLE 18.    FIFTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 19.    GLOBAL CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 20.    BRANDED CEPHALOSPORIN DRUGS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 21.    GENERIC CEPHALOSPORIN DRUGS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 22.    GLOBAL CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 23.    CEPHALOSPORIN DRUGS THAT ARE GIVEN AS INJECTION
TABLE 24.    CEPHALOSPORIN INJECTIONS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 25.    ORAL CEPHALOSPORIN DRUGS
TABLE 26.    ORAL CEPHALOSPORIN DRUGS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 27.    GLOBAL CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 28.    CEPHALOSPORIN DRUGS USED TO TREAT RESPIRATORY TRACT INFECTION
TABLE 29.    CEPHALOSPORIN MARKET FOR RESPIRATORY TRACT INFECTION, BY REGION, 2017–2025 ($MILLION)
TABLE 30.    CEPHALOSPORIN DRUGS USED TO TREAT SKIN INFECTION
TABLE 31.    CEPHALOSPORIN MARKET FOR SKIN INFECTION, BY REGION, 2017–2025 ($MILLION)
TABLE 32.    CEPHALOSPORIN DRUGS USED TO TREAT EAR INFECTION
TABLE 33.    CEPHALOSPORIN MARKET FOR EAR INFECTION, BY REGION, 2017–2025 ($MILLION)
TABLE 34.    CEPHALOSPORIN DRUGS USED TO TREAT URINARY TRACT INFECTION
TABLE 35.    CEPHALOSPORIN MARKET FOR URINARY TRACT INFECTION, BY REGION, 2017–2025 ($MILLION)
TABLE 36.    CEPHALOSPORIN DRUGS USED TO TREAT INFECTION CAUSED DUE TO GONORRHOEA
TABLE 37.    CEPHALOSPORIN MARKET FOR SEXUALLY TRANSMITTED INFECTION,  BY REGION, 2017–2025 ($MILLION)
TABLE 38.    CEPHALOSPORIN DRUGS USED FOR OTHER APPLICATIONS
TABLE 39.    CEPHALOSPORIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2025 ($MILLION)
TABLE 40.    GLOBAL CEPHALOSPORIN MARKET, BY REGION ($MILLION), 2017–2025
TABLE 41.    NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 42.    U.S. CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 43.    U.S. CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 44.    U.S. CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 45.    U.S. CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 46.    CANADA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 47.    CANADA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 48.    CANADA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 49.    CANADA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 50.    MEXICO CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 51.    MEXICO CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 52.    MEXICO CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 53.    MEXICO CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 54.    NORTH AMERICA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 55.    NORTH AMERICA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 56.    NORTH AMERICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 57.    NORTH AMERICA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 58.    TOP FIVE EUROPEAN COUNTRIES PER STI, 2000–2013
TABLE 59.    EUROPE CEPHALOSPORIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 60.    GERMANY CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 61.    GERMANY CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 62.    GERMANY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 63.    GERMANY CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 64.    FRANCE CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 65.    FRANCE CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 66.    FRANCE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 67.    FRANCE CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 68.    UK CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 69.    UK CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 70.    UK CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 71.    UK CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 72.    ITALY CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 73.    ITALY CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 74.    ITALY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 75.    ITALY CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 76.    SPAIN CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 77.    SPAIN CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 78.    SPAIN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 79.    SPAIN CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 80.    REST OF EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 81.    REST OF EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 82.    REST OF EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 83.    REST OF EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 84.    EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 85.    EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 86.    EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 87.    EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 88.    ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 89.    JAPAN CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 90.    JAPAN CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 91.    JAPAN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 92.    JAPAN CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 93.    CHINA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 94.    CHINA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 95.    CHINA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 96.    CHINA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 97.    INDIA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 98.    INDIA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 99.    INDIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 100.    INDIA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 101.    AUSTRALIA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 102.    AUSTRALIA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 103.    AUSTRALIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 104.    AUSTRALIA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 105.    SOUTH KOREA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 106.    SOUTH KOREA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 107.    SOUTH KOREA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 108.    SOUTH KOREA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 109.    REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 110.    REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 111.    REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 112.    REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 113.    ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 114.    ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 115.    ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 116.    ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 117.    LAMEA CEPHALOSPORIN MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 118.    BRAZIL CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 119.    BRAZIL CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 120.    BRAZIL CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 121.    BRAZIL CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 122.    SOUTH AFRICA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 123.    SOUTH AFRICA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 124.    SOUTH AFRICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 125.    SOUTH AFRICA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 126.    SAUDI ARABIA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 127.    SAUDI ARABIA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 128.    SAUDI ARABIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 129.    SAUDI ARABIA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 130.    REST OF LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 131.    REST OF LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 132.    REST OF LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 133.    REST OF LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 134.    LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2017–2025 ($MILLION)
TABLE 135.    LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 136.    LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017–2025 ($MILLION)
TABLE 137.    LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2017–2025 ($MILLION)
TABLE 138.    ALLERGAN: COMPANY SNAPSHOT
TABLE 139.    ALLERGAN: OPERATING SEGMENTS
TABLE 140.    ALLERGAN: PRODUCT PORTFOLIO
TABLE 141.    BMS: COMPANY SNAPSHOT
TABLE 142.    BMS: PRODUCT PORTFOLIO
TABLE 143.    ROCHE: COMPANY SNAPSHOT
TABLE 144.    ROCHE: OPERATING SEGMENTS
TABLE 145.    ROCHE: PRODUCT PORTFOLIO
TABLE 146.    GSK: COMPANY SNAPSHOT
TABLE 147.    GSK: OPERATING SEGMENTS
TABLE 148.    GSK: PRODUCT PORTFOLIO
TABLE 149.    LUPIN LIMITED: COMPANY SNAPSHOT
TABLE 150.    LUPIN LIMITED: OPERATING SEGMENTS
TABLE 151.    LUPIN LIMITED: PRODUCT PORTFOLIO
TABLE 152.    MERCK: COMPANY SNAPSHOT
TABLE 153.    MERCK: OPERATING SEGMENTS
TABLE 154.    MERCK: PRODUCT PORTFOLIO
TABLE 155.    NOVARTIS AG: COMPANY SNAPSHOT
TABLE 156.    NOVARTIS: OPERATING SEGMENTS
TABLE 157.    NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 158.    PFIZER: COMPANY SNAPSHOT
TABLE 159.    PFIZER: OPERATING SEGMENTS
TABLE 160.    PFIZER: PRODUCT PORTFOLIO
TABLE 161.    SANOFI: COMPANY SNAPSHOT
TABLE 162.    SANOFI: OPERATING SEGMENTS
TABLE 163.    SANOFI: PRODUCT PORTFOLIO
TABLE 164.    TEVA: COMPANY SNAPSHOT
TABLE 165.    TEVA: OPERATING SEGMENTS
TABLE 166.    TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    CEPHALOSPORIN MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    MARKET SHARE ANALYSIS, 2017
FIGURE 04.    BARGAINING POWER OF BUYERS
FIGURE 05.    BARGAINING POWER OF SUPPLIERS
FIGURE 06.    THREAT OF SUBSTITUTION
FIGURE 07.    THREAT OF NEW ENTRANT
FIGURE 08.    COMPETITIVE RIVALRY
FIGURE 09.    ALLERGAN: NET SALES, 2015–2017 ($MILLION)
FIGURE 10.    ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 11.    BMS: REVENUE, 2015–2017 ($MILLION)
FIGURE 12.    BMS: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 13.    BMS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 14.    ROCHE: NET SALES, 2015–2017 ($MILLION)
FIGURE 15.    ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 16.    GSK: NET SALES, 2015–2017 ($MILLION)
FIGURE 17.    GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 18.    GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 19.    LUPIN LIMITED: NET SALES, 2016–2018 ($MILLION)
FIGURE 20.    LUPIN LIMITED: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 21.    MERCK: NET SALES, 2015–2017 ($MILLION)
FIGURE 22.    MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 23.    MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 24.    NOVARTIS: NET SALES, 2015–2017 ($MILLION)
FIGURE 25.    NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26.    NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27.    PFIZER: NET SALES, 2015–2017 ($MILLION)
FIGURE 28.    PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29.    PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30.    SANOFI: NET SALES, 2015–2017 ($MILLION)
FIGURE 31.    SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32.    SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33.    TEVA: NET SALES, 2015–2017 ($MILLION)
FIGURE 34.    TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35.    TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 
 

Rise in global prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea constitutes a major proportion of health and economic burden. Therefore, advent of superior drugs is a necessary treatment option of these infections.

Upsurge in the population suffering from infections such as sexually transmitted infections boosts the market growth. Moreover, increased approvals of drugs and rise in awareness about various infections & antibiotic resistance fuel the growth of the market. Increase in use of combination therapies further leads to the growth of the market.

LAMEA is expected to grow at the highest CAGR during the study period. This is attributable to easy obtainability of cephalosporin over the counter and no obligation on their usage in this region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to high prevalence of infectious diseases and rise in demand for cephalosporin.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cephalosporin Market

  • Online Only
  • $3,456  $3,041
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,379
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370  $4,296
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $4,838
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $6,297
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Access
  • $0.00
  • Published Content E-Access
  • Company Profiles E-Access
  • Newly Added Content Access
  • 10 PDF Downloads
  • 5 Excel Data Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly
    ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample